- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
263
ovErviEw oF tHE EvalUation oF lowEr Urinary tract dysFUnction
exceeds the anatomical capacity, under the influence of the elastic forces in the bladder wall. These patients pass small volumes of urine, frequently without any control. Chronic retention is an important condition to consider in any patient, as many will present with renal impairment.
During the voiding phase the reverse activity to the storage phase must occur. Voiding symptoms (poor stream, hesitancy, interruption, and straining) are due to either loss of detrusor power or progressive outflow obstruction which, it is presumed, may progressively lead to detrusor failure and retention.
Voiding Phase
The bladder must cease relaxing and instead contract to expel the urine and the urethra and sphincteric mechanisms must“open”to decrease the outlet resistance and allow passage of urine. Voiding should be efficient and there should be minimal or no urine remaining in the bladder at the end of the voiding phase.
Micturition initiated by the cerebral cortex is likely to involve a complex series of bladder– brain stem reflexes.
During voiding:
•Urethral relaxation precedes detrusor contraction;
•There is simultaneous relaxation of the pelvic floor muscles; and
•There is accompanying funneling of the bladder neck and detrusor contraction occurs to forcefully expel urine
The mechanism of these changes is not clear. It is likely that:
•Increased activity within parasympathetic neurones results in removal of central inhibitory influences acting on the sacral centers; and
•Voiding is initiated under the influence of pontine medullary centers.
There is therefore parasympathetically controlled detrusor contraction associated with a corresponding relaxation of the urethra/prostate/bladder neck complex resulting from reciprocal nerve-mediated inhibition of the sympathetic nerve-mediated outflow.
In addition to these primary actions other important secondary events are:
•Contraction of the diaphragm and anterior abdominal wall muscles;
•Relaxation of the pelvic floor; and
•Specific behavioral changes associated with voiding.
Return to Storage Phase
At the end of voiding, the proximal urethra is closed in a retrograde fashion, thus milking urine back into the bladder. This “milkback” is seen during contrast studies of the lower urinary tract when the patient is asked to stop voiding. Following this the bladder returns to a state of relaxation. Once these events have been completed, the sacral centers are re-inhibited by the cortex and the next filling cycle starts.
Urodynamic Parameters
Urodynamic Techniques
In any patient presenting with lower urinary tract symptoms, it is essential to carry out a complete evaluation of the patient – both subjectively and objectively. It is imperative that the exact functional derangement is defined and the precise etiological factors identified. Prior to urodynamics a careful history and examination are essential and a balance struck between treatment modalities available and patient expectations.
Urodynamic techniques assume a variety of forms and need to be considered to represent a hierarchical series of increasingly complex tests.
Volume Voided Charts
The urodynamic value of the simple voided volume chart is often overlooked – an important omission since this is a natural volumetric urodynamic record of bladder function. The volume/frequency chart is a simple noninvasive tool used in the evaluation of patients with voiding dysfunction, and in particular, in those with increased urinary frequency and incontinence.4
Volume/frequency charts help define severity of symptoms and add objectivity to the history. One can readily diagnose increased urinary frequency secondary to high urinary output and from physiological nocturnal diuresis.A record of fluid intake helps identify an easily treatable cause
264
Practical Urology: EssEntial PrinciPlEs and PracticE
of urinary frequency. The recommended daily |
Table 20.2. Useful information listed in voiding diaries |
|||
fluid intake of six to eight glasses of fluids |
24 h frequency |
|
number of voids in 24 h |
|
(1 glass=8 oz, 1 oz=30 mL; so nearly 2 L for all |
|
|||
|
|
|
||
fluids/day) is often misconstrued by the patient as |
daytime frequency |
number of voids whist awake |
||
the doctor’s recommendation to drink six to eight |
nocturia |
|
number of voids during sleep |
|
glasses of water daily in addition to the basic fluid |
|
|||
24 h production |
|
total volume of voids in 24 h |
||
needs.This excessive fluid intake frequently results |
|
|||
in frequency, urgency, and may worsen urinary |
Polyuria |
|
>2.8 l urine production in 24 h |
|
incontinence. It is important to review these sim- |
|
|||
nocturnal urine |
|
Excluding last void before sleep, |
||
ple guidelines with the patient and discover if their |
|
|||
craving for fluids is not prompted by a sensation |
volume |
|
total volume voided during |
|
of dry mouth,by the desire to avoid constipation,a |
|
|
sleep hours, including first |
|
|
|
void in morning |
||
fear of another bladder infection, or a special diet |
|
|
||
|
|
|
||
to lose weight. The average maximum voided vol- |
nocturnal polyuria |
nocturnal urine volume/24 h |
||
ume represents the patient’s functional capacity, |
|
|
production > 33% |
|
knowledge of which is useful to know to prevent |
Maximum voided |
largest volume voided in a |
||
overfilling of the bladder during cystometry. |
||||
volume |
|
single void |
||
A normal bladder fills to a volume approxi- |
Pad usage |
|
number of pads used during a |
|
mating its functional capacity and the chart |
|
|||
records a series of sizable (300–500 mL) and |
|
|
specified period |
|
|
|
|
||
fairly consistent volumes. |
Frequency of |
|
number of incontinence |
|
An overactive bladder contracts at variable |
incontinence |
|
episodes in a specified time |
|
degrees of distension before full capacity, errone- |
episodes |
|
period |
|
ously informing the patient that it is full,resulting |
Frequency of urgency |
number of urgency episodes in |
||
in urinary frequency and low and varying voided |
||||
episodes |
|
a specified time period |
||
volumes. In addition, frequency/volume charts |
|
|
|
|
provide important feedback to the practitioner |
|
|
|
|
and patient necessary to objectively evaluate the |
during the hours of sleep. This is not of |
|||
effectiveness of any therapies used in the treat- |
||||
ment of the urinary dysfunction. These charts |
urological origin and is commonly due to |
|||
can be combined with measurements of episodes |
fluid redistribution whilst lying down such |
|||
of urgency, pad usage, or incontinence. They give |
as occurs in congestive cardiac failure |
|||
an indication of the severity of symptoms, add |
A voiding diary can also be used to evaluate |
|||
objectivity to the history and allow for temporal |
||||
therapeutic responses, and is an excellent tool |
||||
relationships to be appreciated. Patients are given |
||||
for providing |
biofeedback during bladder |
|||
a measuring jug and a“diary”and asked to record |
||||
retraining drills. Bladder retraining programs |
||||
their urinary activities, keeping to their normal |
||||
aim to allow patients to retrain their bladder |
||||
daily routine for up to 1 week. Also recorded are |
||||
and work on the principle of holding a voiding |
||||
times of sleep and wake (see Table 20.2). |
||||
desire for progressively longer intervals thus |
||||
Abnormal findings include: |
||||
stretching the bladder, to decrease voiding fre- |
||||
|
||||
• Increased frequency and normal volumes – |
quency to an acceptable five or six times a day. |
|||
|
|
|
||
this may be related to a high fluid intake, |
|
|
|
|
diabetes mellitus, or insipidus, but is most |
Pad Testing |
|
|
|
often habitual |
|
|
||
• Reduced volumes with variation in the vol- |
The subjective assessment of incontinence is |
|||
ume voided – suggestive of detrusor overac- |
often difficult to interpret and does not reliably |
|||
tivity,due to bladder contraction at different |
indicate degree of abnormality. Not all patients |
|||
degrees of distension, i.e. abnormal signal- |
who complain of urinary incontinence are in |
|||
ing prior to reaching maximum capacity |
fact incontinent during a cystometric examina- |
|||
• Increased nocturnal production (noctur- |
tion. Pad testing is a simple, noninvasive objec- |
|||
nal polyuria) – where more than one third |
tive method for detecting and quantifying urine |
|||
of the 24 h urine production is produced |
leakage.5–7 To |
obtain a representative result, |
265
ovErviEw oF tHE EvalUation oF lowEr Urinary tract dysFUnction
especially in subjects with variable or intermittent urinary incontinence,the test should occupy as long a period as possible, in circumstances which should approximate those of everyday life; yet be as practical as possible in the available circumstances and be carried out in a standardized fashion.
On the basis of pilot studies performed in various centers, we would recommend a 1 h test period during which a series of standard activities are carried out. This test can be extended by further 1 h periods if the result of the first 1 h test was not considered representative by either the patient or the investigator. Alternatively the test can be repeated having filled the bladder to a defined volume.
The total amount of urine lost during the test period is determined by weighing a collecting device such as a nappy, absorbent pad, or condom appliance. A nappy or pad should be worn inside waterproof underpants or should have a waterproof backing. Care should be taken to use a collecting device of adequate capacity. Immediately before the test begins the collecting device is weighted to the nearest gram.
Typical Test Schedule
a.Test is started without the patient voiding.
b.Pre-weighed collecting device is put on and first 1 h test period begins.
c.Subject drinks 500 mL sodium free liquid within a short period (maximum 15 min), then sits or rests.
d.Half hour period: subject walks, including stair climbing equivalent to one flight up and down.
e.During the remaining period the subject performs the following activities:
i.Standing up from sitting, ten times
ii.Coughing vigorously, ten times
iii.Running on the spot for 1 min
iv.Bending to pick up small object from floor, five times
v.Wash hands in running water for 1 min
f.At the end of the 1 h test, the collecting device is removed and weighed.
g.If the test is regarded as representative the subject voids and the volume is recorded.
h.Otherwise the test is repeated preferably without voiding.
If the collecting device becomes saturated or filled during the test it should be removed and weighed, and replaced by a fresh device. The activity programmed may be modified according to the subject’s physical ability.
Interpretation: The total weight of urine lost during the test period is taken to be equal to the gain in weight of the collecting device(s). An increase in the weight of the pad of less than 1 g in 1 h is not considered a sign of incontinence since a weight gain of up to 1 g may be due to weighing errors, sweating, or vaginal discharge. Evaporation is not important. The test should not be performed during a menstrual period and be cautious that the patient may influence the test result by voluntarily voiding. A negative result should be interpreted with caution, the test may need to be repeated or supplemented with a longer test. The reproducibility of the 1 h pad test is relatively poor. If substantial variations from the usual test schedule occur, this should be recorded so that the same schedule can be used on subsequent occasions. In principle the subject should not void during the test period. If the patient experiences urgency, then she should be persuaded to postpone voiding and to perform as many of the activities in section (e) as possible in order to detect leakage. Before voiding the collection device is removed for weighing. If inevitable voiding cannot be postponed then the test is terminated. The voided volume and the duration of the test should be recorded. For subjects not completing the full test the results may require separate analysis, or the test may be repeated after rehydration.
Normal values: The hourly pad weight increase in continent women varies from 0.0 to 2.1 g/h, averaging 0.26 g/h.With the 1-h ICS pad test, the upper limit (99% confidence limit) has been found to be 1.4 g/h.
Home pad tests lasting 24–48 h are superior to 1 h test in detecting urinary incontinence. The normal upper limit in a 24 h test is 8 g. Though longer tests are better screening tests for incontinence they are less practical and more cumbersome.
Additional procedures intended to give information of diagnostic value are permissible provided they do not interfere with the basic test. For example, additional changes and weighing of the collecting device can give information about the timing of urine loss. The absorbent